CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Tomoo Nakagawa, Taku Kobayashi, Kiyohiro Nishikawa, Fumika Yamada, Satoshi Asai, Yukinori Sameshima, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi
Intest Res. 2019;17(4):504-515.   Published online August 23, 2019
DOI: https://doi.org/10.5217/ir.2019.00030

Excel Download

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
Intestinal Research. 2019;17(4):504-515   Crossref logo
Link1 Link2 Link3

P536 Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i487-i487   Crossref logo
Link1 Link2

Retraction: An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab
Journal of Crohn's and Colitis. 2020;14(3):428-428   Crossref logo
Link1 Link2

T04.02.18 SWITCHING FROM INFLIXIMAB ORIGINATOR TO THE BIOSIMILAR (CT-P13) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY ABOUT EFFECTIVENESS AND SAFETY
Digestive and Liver Disease. 2020;52:S134-S135   Crossref logo
Link1 Link2

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
Therapeutic Advances in Gastroenterology. 2016;9(3):322-329   Crossref logo
Link1 Link2 Link3

Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report
Clinical Case Reports. 2019;7(11):2049-2053   Crossref logo
Link1 Link2 Link3 Link4

P.07.13 SAFETY AND EFFICACY OF INFLIXIMAB BIOSIMILAR SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE WHO UNDERWENT A SWITCH FROM INFLIXIMAB BIOSIMILAR CT-P13
Digestive and Liver Disease. 2019;51:e227   Crossref logo
Link1 Link2

Infliximab biosimilar CT-P13 for inflammatory bowel disease
The Lancet Gastroenterology & Hepatology. 2018;3(6):373-375   Crossref logo
Link1 Link2

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan
Journal of Gastroenterology and Hepatology. 2021;36(8):2091-2100   Crossref logo
Link1 Link2 Link3

P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study
Journal of Crohn's and Colitis. 2020;14(Supplement_1):S396-S397   Crossref logo
Link1 Link2